K Eckardt1, C May, M Koenen, J Eckel. 1. Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Auf'm Hennekamp 65, D-40225, Dusseldorf, Germany.
Abstract
AIMS/HYPOTHESIS: Mitogenic activity of insulin and insulin analogues and the involvement of the IGF-1 receptor (IGF-1R) is still a controversial issue. We compared levels of the proteins IGF-1R and insulin receptor (InsR) in fibroblasts and smooth muscle cells from healthy donors and assessed the downstream signalling and growth-promoting activity of insulin and insulin analogues. METHODS: DNA synthesis was monitored in human fibroblasts and coronary artery smooth muscle cells. Using small interfering RNAs, the levels of IGF-1 and InsR were reduced by 95 and 75%, respectively. RESULTS: Enhanced mitogenic potency of insulin and insulin analogues was observed which correlated with increased levels of IGF-1R and/or IRS-1. A reduction in the IGF-1R level significantly blunted stimulation of Akt phosphorylation by IGF-1, AspB10 and glargine by 72, 58 and 40%, respectively. Akt phosphorylation in response to insulin remained unaffected. Silencing of InsR did not significantly alter Akt phosphorylation in response to IGF-1, AspB10 and glargine. IGF-1R knockdown reduced the stimulation of DNA synthesis in response to IGF-1 and glargine to a level identical to that produced by insulin. CONCLUSIONS/ INTERPRETATION: These data show a prominent role of IGF-1R/Akt signalling in mediating the mitogenic effects of insulin analogues. Regular insulin stimulates DNA synthesis by exclusively activating InsR, whereas insulin analogues mainly signal through IGF-1R. It is suggested that inter-individual differences in the levels of proteins of the IGF-1R system may function as a critical determinant of the mitogenic potency of insulin analogues.
AIMS/HYPOTHESIS: Mitogenic activity of insulin and insulin analogues and the involvement of the IGF-1 receptor (IGF-1R) is still a controversial issue. We compared levels of the proteins IGF-1R and insulin receptor (InsR) in fibroblasts and smooth muscle cells from healthy donors and assessed the downstream signalling and growth-promoting activity of insulin and insulin analogues. METHODS: DNA synthesis was monitored in human fibroblasts and coronary artery smooth muscle cells. Using small interfering RNAs, the levels of IGF-1 and InsR were reduced by 95 and 75%, respectively. RESULTS: Enhanced mitogenic potency of insulin and insulin analogues was observed which correlated with increased levels of IGF-1R and/or IRS-1. A reduction in the IGF-1R level significantly blunted stimulation of Akt phosphorylation by IGF-1, AspB10 and glargine by 72, 58 and 40%, respectively. Akt phosphorylation in response to insulin remained unaffected. Silencing of InsR did not significantly alter Akt phosphorylation in response to IGF-1, AspB10 and glargine. IGF-1R knockdown reduced the stimulation of DNA synthesis in response to IGF-1 and glargine to a level identical to that produced by insulin. CONCLUSIONS/ INTERPRETATION: These data show a prominent role of IGF-1R/Akt signalling in mediating the mitogenic effects of insulin analogues. Regular insulin stimulates DNA synthesis by exclusively activating InsR, whereas insulin analogues mainly signal through IGF-1R. It is suggested that inter-individual differences in the levels of proteins of the IGF-1R system may function as a critical determinant of the mitogenic potency of insulin analogues.
Authors: G Perriello; S Pampanelli; F Porcellati; A Avogaro; E Bosi; G Petrella; S Squatrito; S Furneri; G Marra; L Vitali; M Previti; D Cucinotta Journal: Diabet Med Date: 2005-05 Impact factor: 4.359
Authors: L J Slieker; G S Brooke; R D DiMarchi; D B Flora; L K Green; J A Hoffmann; H B Long; L Fan; J E Shields; K L Sundell; P L Surface; R E Chance Journal: Diabetologia Date: 1997-07 Impact factor: 10.122
Authors: Theodore P Ciaraldi; Susan A Phillips; Leslie Carter; Vanita Aroda; Sunder Mudaliar; Robert R Henry Journal: J Clin Endocrinol Metab Date: 2005-07-19 Impact factor: 5.958
Authors: K Staiger; H Staiger; M A Schweitzer; E Metzinger; B Balletshofer; H-U Häring; M Kellerer Journal: Diabetologia Date: 2005-08-03 Impact factor: 10.122
Authors: M Warnken; U Reitzenstein; A Sommer; M Fuhrmann; P Mayer; H Enzmann; U R Juergens; K Racké Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2010-10-06 Impact factor: 3.000
Authors: Vinit N Varu; Sadie S Ahanchi; Melissa E Hogg; Hussein A Bhikhapurwala; Amy Chen; Daniel A Popowich; Ashley K Vavra; Janet Martinez; Qun Jiang; Joseph E Saavedra; Joseph A Hrabie; Larry K Keefer; Melina R Kibbe Journal: Am J Physiol Heart Circ Physiol Date: 2010-06-18 Impact factor: 4.733
Authors: Subramanyam N Murthy; Sergiy Sukhanov; Jennifer McGee; Joel A Greco; Surabhi Chandra; Patrice Delafontaine; Philip J Kadowitz; Dennis B McNamara; Vivian A Fonseca Journal: Mol Cell Biochem Date: 2009-04-10 Impact factor: 3.396
Authors: Christine Bonnesen; Gitte-Mai Nelander; Bo Falck Hansen; Pia Jensen; Jonas S Krabbe; Marianne B Jensen; Anne Charlotte Hegelund; Jette E Svendsen; Martin B Oleksiewicz Journal: Cell Biol Toxicol Date: 2009-11-08 Impact factor: 6.691